Tanja Obradovic Tracks Progress of HARMONi-3 and HARMONi-7 Trials in Advanced NSCLC
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn about a paper by Jianjun Zhang et al. published on Journal of Clinical Oncology:
“Potential of dual inhibition of PD-1 and the anti-angiogenesis via blocking VEGF to deliver superior efficacy over PD-1 inhibitors is a very hot area of interest this and incoming year as data from ongoing trials matures. Few days ago Summit Therapeutics, Inc. announced presentation of Ivonescimab data from Phase III HARMONi trial to be showcased at Presidential Symposium at 2025 World Conference on Lung Cancer (WCLC2025) in September.
HARMONi is a global, double-blinded, placebo-controlled, Phase III study evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI).
Based on results disclosed so far overall survival (OS) data may look quite good. Still, all eyes are on comparison of ivonescimab to Keytruda (pembrolizumab) in ongoing Phase III studies HARMONi-3 (NCT05899608) and HARMONi-7 (NCT06767514). As of now both trials are enrolling and HARMONi-3 is likely to report first with being open since 2023 and currently at 167 global locations. Not much was revealed from HARMONi-3 at ASCO2025 (Abstract from the meeting) and community will be on the lookout for any interim analysis updates.”
Title: A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3
Authors: Jianjun Zhang, Jun Cai, Hui Wang, Yan Yu, Joaquim Bosch-Barrera, Reyes Bernabé, Zoran Andric, Firas Benyamine Badin, Yusuke Okuma, Paul K. Paik, Jarushka Naidoo, Haralabos Kalofonos, Bo Wang, Robert M. Jotte, Nathan A. Pennell, Jonathan W. Riess, Deborah Blythe Doroshow, Makoto Nishio, Jorge Arturo Alatorre-Alexander, and Shun Lu
Read the full article.
More posts featuring Tanja Obradovic on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023